Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Simulations Plus, Inc.
Simulations Plus, Inc. News
Simulations Plus, Inc. Quantitative Score
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Simulations Plus, Inc. Earnings & Revenue
Simulations Plus, Inc. Financials
Table Compare
Compare SLP metrics with: | |||
|---|---|---|---|
Earnings & Growth | SLP | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SLP | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SLP | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SLP | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Simulations Plus, Inc. Income
Simulations Plus, Inc. Balance Sheet
Simulations Plus, Inc. Cash Flow
Simulations Plus, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Neutral |
| Return on Assets | Buy |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Simulations Plus, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.2400 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2024-08-05 | 0.06 | Quarterly |
| 2024-05-06 | 0.06 | Quarterly |
| 2024-02-05 | 0.06 | Quarterly |
| 2023-11-06 | 0.06 | Quarterly |
| 2023-08-07 | 0.06 | Quarterly |
Simulations Plus, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Simulations Plus, Inc. Executives
| Name | Role |
|---|---|
| Mr. Shawn M. O'Connor | Chief Executive Officer |
| Mr. William Frederick | Chief Operating Officer, Chief Financial Officer & Secretary |
| Mr. Daniel Szot | Chief Revenue Officer |
| Mr. John Anthony DiBella M.S. | President of PBPK & Cheminformatics Solutions |
| Mr. Steven Chang | President of Quantitative Systems Pharmacology |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Shawn M. O'Connor | Chief Executive Officer | Male | 1960 | 667.62K |
| Mr. William Frederick | Chief Operating Officer, Chief Financial Officer & Secretary | Male | 1964 | 512.28K |
| Mr. Daniel Szot | Chief Revenue Officer | Male | 432.28K | |
| Mr. John Anthony DiBella M.S. | President of PBPK & Cheminformatics Solutions | Male | 1980 | 364.62K |
| Mr. Steven Chang | President of Quantitative Systems Pharmacology | Male | 1968 | 359.41K |
Simulations Plus, Inc. Insider Trades
| Date | 3 Feb |
| Name | Paglia John Kenneth |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 787 |
| Date | 3 Feb |
| Name | WEINER DANIEL L |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 787 |
| Date | 3 Feb |
| Name | Evans Sharlene |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 787 |
| Date | 3 Feb |
| Name | LaVange Lisa |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 787 |
| Date | 3 Feb |
| Name | WOLTOSZ WALTER S |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 5579 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 3 Feb | Paglia John Kenneth | Director | Acquired | A-Award | 787 |
| 3 Feb | WEINER DANIEL L | Director | Acquired | A-Award | 787 |
| 3 Feb | Evans Sharlene | Director | Acquired | A-Award | 787 |
| 3 Feb | LaVange Lisa | Director | Acquired | A-Award | 787 |
| 3 Feb | WOLTOSZ WALTER S | Director, 10 percent owner | Disposed | S-Sale | 5579 |